Document is current
Any future updates will be listed below
-
Authors
Adashek, Jacob J. https://orcid.org/0000-0003-4272-312X
Nikanjam, Mina
Kurzrock, Razelle https://orcid.org/0000-0003-4110-1214
- License Information
-
More Information
Article History
Accepted: 28 January 2025
First Online: 6 March 2025
Competing interests
: J.J.A. serves on the advisory board of CureMatch and is a consultant for datma. R.K. has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, MedImmune, Merck Serono, Omniseq, Pfizer, Sequenom, Sysmex, Takeda and TopAlliance and from the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Daiichi, Datar Cancer Genetics, EISAI, EMD Serono, EOM Pharmaceuticals, Iylon, Jackson Laboratories, LabCorp, Lanauria Therapeutics, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Quanta Therapeutics, Recordati, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch, Inc.; serves on the Board of CureMatch and CureMetrix and XZOM, and is a co-founder of CureMatch. M.N. declares no competing interests.
